ARA-290
ARA-290
A synthetic peptide derived from erythropoietin that promotes tissue protection and neuropathic pain relief without stimulating red blood cell production.
Typical Cost
$100-250/vial (10mg)
Status
Research
Peptide Profile
ARA-290
Mechanism of Action
Activates the innate repair receptor, triggering anti-inflammatory and tissue-protective responses. Promotes nerve regeneration and reduces neuropathic pain without hematopoietic effects.
Common Dosages
subcutaneous
1-4mg
2-3x weekly · 4-8 weeks
Benefits
Neuropathic pain relief
Nerve regeneration
Tissue protection
Anti-inflammatory
No blood cell effects
Side Effects
Mild injection site reactions
Limited long-term data
Key Research
ARA-290 in diabetic neuropathy
Demonstrated significant pain reduction and nerve fiber regeneration in Phase 2 trials
Regulatory Status
Phase II/III clinical trials for neuropathic pain and sarcoidosis. Not FDA-approved yet.
Contraindications
- ⚠Pregnancy/breastfeeding
- ⚠Active cancer
GLP-1 users experiencing neuropathy may find ARA-290 beneficial alongside SeraVia's nerve-supporting formulations.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.